Suchergebnisse - "Subbiah, Vivek"

PubPharm (63)

1

Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies

enthalten in: Cancer research communications | 2024

von Subbiah, V. | Coleman, N. | Piha-Paul, S. | +15

2

Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors

enthalten in: Cancer medicine | 2024

von Coleman, N. | Stephen, B. | Fu, S. | +10

3

A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors

enthalten in: The oncologist | 2023

von Nelson, B. | Tsimberidou, A. | Fu, X. | +9

4

Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von Subbiah, V. | Chawla, S. | Conley, A. | +16

5

A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation

enthalten in: Cancer chemotherapy and pharmacology | 2023

von Piha-Paul, S. | Tseng, C. | Tran, H. | +13

6

A phase 1/2a safety, pharmacokinetics, and efficacy study of the novel nucleoside analog FF-10502-01 for the treatment of advanced solid tumors

enthalten in: Cancer | 2023

von Janku, F. | Javle, M. | Sen, S. | +14

7

Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia : phase I trials

enthalten in: Nature medicine | 2023

von Yap, T. | Daver, N. | Mahendra, M. | +46

CommentIn: Nat Med. 2023 Jan;29(1):29-30. - PMID 36658424

8

Examining Stripes on a Herd of Zebras : Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von Moyers, J. | Pestana, R. | Roszik, J. | +20

9

Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer : Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Drilon, A. | Subbiah, V. | Gautschi, O. | +15

CommentIn: J Clin Oncol. 2023 Jan 10;41(2):410-412. - PMID 36122320

10

Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001) : a phase 1/2, open-label, basket trial

enthalten in: The Lancet. Oncology | 2022

von Subbiah, V. | Wolf, J. | Konda, B. | +12

CommentIn: Lancet Oncol. 2022 Oct;23(10):1235-1237. - PMID 36108663

1
2
3
4
5
6
7
Nächster »
[7]